MCID: DMN012
MIFTS: 14

Dementia - Subcortical

Categories: Mental diseases

Aliases & Classifications for Dementia - Subcortical

MalaCards integrated aliases for Dementia - Subcortical:

Name: Dementia - Subcortical 51
Subcortical Dementia 29 69

Classifications:



Summaries for Dementia - Subcortical

NINDS : 51 Binswanger's disease (BD), also calledĀ subcortical vascular dementia, is a type of dementia caused by widespread, microscopic areas of damage to the deep layers of white matter in the brain. The damage is the result of the thickening and narrowing (atherosclerosis) of arteries that feed the subcortical areas of the brain. Atherosclerosis (commonly known as "hardening of the arteries") is a systemic process that affects blood vessels throughout the body. It begins late in the fourth decade of life and increases in severity with age. As the arteries become more and more narrowed, the blood supplied by those arteries decreases and brain tissue dies. A characteristic pattern of BD-damaged brain tissue can be seen with modern brain imaging techniques such as CT scans or magnetic resonance imaging (MRI). The symptoms associated with BD are related to the disruption of subcortical neural circuits that control what neuroscientists callexecutive cognitive functioning: short-term memory, organization, mood, the regulation of attention, the ability to act or make decisions, and appropriate behavior. The most characteristic feature of BD is psychomotor slowness - an increase in the length of time it takes, for example, for the fingers to turn the thought of a letter into the shape of a letter on a piece of paper. Other symptoms include forgetfulness (but not as severe as the forgetfulness of Alzheimer's disease), changes in speech, an unsteady gait, clumsiness or frequent falls, changes in personality or mood (most likely in the form of apathy, irritability, and depression), and urinary symptoms that aren't caused by urological disease. Brain imaging, which reveals the characteristic brain lesions of BD, is essential for a positive diagnosis. Ā 

MalaCards based summary : Dementia - Subcortical, also known as subcortical dementia, is related to huntington disease-like 2 and dementia. The drugs Galantamine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and eye.

Related Diseases for Dementia - Subcortical

Diseases related to Dementia - Subcortical via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 huntington disease-like 2 10.9
2 dementia 9.9
3 vascular dementia 9.7
4 binswanger's disease 9.7
5 vascular disease 9.6

Graphical network of the top 20 diseases related to Dementia - Subcortical:



Diseases related to Dementia - Subcortical

Symptoms & Phenotypes for Dementia - Subcortical

Drugs & Therapeutics for Dementia - Subcortical

Drugs for Dementia - Subcortical (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Galantamine Approved Phase 4 357-70-0 9651
2
Donepezil Approved Phase 4,Phase 2 120014-06-4 3152
3
Cilostazol Approved Phase 4,Phase 2 73963-72-1 2754
4 Cholinergic Agents Phase 4,Phase 2
5 Cholinesterase Inhibitors Phase 4,Phase 2
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
7 Nootropic Agents Phase 4,Phase 2
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
9 Phosphodiesterase Inhibitors Phase 4,Phase 2
10 Autonomic Agents Phase 4,Phase 3,Phase 2
11 Fibrinolytic Agents Phase 4,Phase 2
12 Respiratory System Agents Phase 4,Phase 2
13 Neuroprotective Agents Phase 4,Phase 2,Phase 3
14 Vasodilator Agents Phase 4,Phase 3,Phase 2
15 Anti-Asthmatic Agents Phase 4,Phase 2
16 Phosphodiesterase 3 Inhibitors Phase 4,Phase 2
17 Platelet Aggregation Inhibitors Phase 4,Phase 2,Phase 3
18 Protective Agents Phase 4,Phase 2,Phase 3
19 Bronchodilator Agents Phase 4,Phase 2
20
Losartan Approved Phase 3 114798-26-4 3961
21
Amlodipine Approved Phase 3 88150-42-9 2162
22
Atenolol Approved Phase 3 29122-68-7 2249
23
Angiotensin II Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
24 3-n-butylphthalide Phase 2, Phase 3
25 calcium channel blockers Phase 3
26 Adrenergic Agents Phase 3
27 Adrenergic Antagonists Phase 3
28 Adrenergic beta-1 Receptor Antagonists Phase 3
29 Adrenergic beta-Antagonists Phase 3
30 Sympatholytics Phase 3
31 Angiotensin II Type 1 Receptor Blockers Phase 3
32 Angiotensin Receptor Antagonists Phase 3
33 Angiotensinogen Phase 3
34 Anti-Arrhythmia Agents Phase 3
35 Antihypertensive Agents Phase 3
36 Calcium, Dietary Phase 3
37
Udenafil Approved, Investigational Phase 2 268203-93-6 6918523
38
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
39
Nitric Oxide Approved Phase 2 10102-43-9 145068
40
Isosorbide Dinitrate Approved Phase 2 87-33-2 6883
41 Phosphodiesterase 5 Inhibitors Phase 2
42 isosorbide-5-mononitrate Phase 2
43 diuretics Phase 2
44 Dopamine agonists Phase 2
45 Natriuretic Agents Phase 2
46 Nitric Oxide Donors Phase 2
47 Dopamine Agents Phase 2
48 Isosorbide Phase 2
49
Menthol Approved 2216-51-5 16666
50
Benzocaine Approved 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show all 29)

id Name Status NCT ID Phase Drugs
1 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Unknown status NCT00523666 Phase 4 Galantamine (Reminyl®);Placebo/Galantamine (Reminyl®)
2 Cilostazol Augmentation Study in Dementia Completed NCT01409564 Phase 4 Cilostazol;Placebo
3 The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND Recruiting NCT02993367 Phase 2, Phase 3 Butylphthalide Soft Capsules;Placebo Butylphthalide Soft Capsules
4 Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function Not yet recruiting NCT03082014 Phase 3 Amlodipine;Losartan;Atenolol
5 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
6 Lacunar Intervention Trial 1 (LACI-1) Recruiting NCT02481323 Phase 2 isosorbide mononitrate;cilostazol
7 Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) Recruiting NCT02450786 Phase 2 Donepezil
8 Hyperbaric Oxygen Therapy for Mild Cognitive Impairment Unknown status NCT02085330
9 Cognitive Impairment , Neuroimaging and Inflammatory Markers in Patients With Subcortical Ischemic Vascular Disease Unknown status NCT01418885
10 Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease Unknown status NCT02330510
11 Rehabilitation of Attention in Patients With MCI and Brain Subcortical Vascular Changes Using the APT-II Completed NCT02033850
12 PET-based Evaluation of Chemotherapy-induced Brain Damage in Lymphoma Completed NCT02601547
13 Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Completed NCT01114815
14 Reshaping the Path of Vascular Cognitive Impairment (VCI) Recruiting NCT02669394
15 The Brain Structure and Neural Network Changing the Before and After Ventriculo-peritoneal Shunting in the Normal Pressure Hydrocephalus Patients Recruiting NCT03092804
16 Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Recruiting NCT02071784
17 DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil Recruiting NCT02711683 DL-3-n-butylphthalide;Donepezil
18 CADASIL Disease Discovery Recruiting NCT02821780
19 Recovery Improved in Covert Stroke With Exercise Recruiting NCT02068391
20 BEAM: Brain-Eye Amyloid Memory Study Recruiting NCT02524405
21 The Swedish BioFINDER 2 Study Recruiting NCT03174938
22 Longitudinal Study of Mild Cognitive Impairment in Parkinson's Disease Recruiting NCT02637089
23 Remote Ischemic Preconditioning for Subcortical Vascular Dementia Active, not recruiting NCT03022149
24 Korea Alzheimer's Disease Neuroimaging Initiative Active, not recruiting NCT01979419
25 Cog-VACCINE: Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia Active, not recruiting NCT02640716
26 The Effect of tDCS on Subcortical Brain Functioning Enrolling by invitation NCT01602276
27 Generation of a Cellular Model of CADASIL From Skin Fibroblasts Enrolling by invitation NCT02032225
28 Sleep Apnea in Early to Mid-Stage Alzheimer's Disease Terminated NCT01400542
29 Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Syndromes Terminated NCT02445469

Search NIH Clinical Center for Dementia - Subcortical

Genetic Tests for Dementia - Subcortical

Genetic tests related to Dementia - Subcortical:

id Genetic test Affiliating Genes
1 Subcortical Dementia 29

Anatomical Context for Dementia - Subcortical

MalaCards organs/tissues related to Dementia - Subcortical:

39
Brain, Skin, Eye

Publications for Dementia - Subcortical

Articles related to Dementia - Subcortical:

id Title Authors Year
1
Word list and story recall elicit different patterns of memory deficit in patients with Alzheimer's disease, frontotemporal dementia, subcortical ischemic vascular disease, and Lewy body dementia. ( 23792693 )
2013

Variations for Dementia - Subcortical

Expression for Dementia - Subcortical

Search GEO for disease gene expression data for Dementia - Subcortical.

Pathways for Dementia - Subcortical

GO Terms for Dementia - Subcortical

Sources for Dementia - Subcortical

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....